merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>FDA-approved safety, quality, and effectiveness controls, unlike compounded versions</answer>

<question_number>2</question_number>
<answer>By offering direct-to-door delivery of vials through their own telehealth platform at competitive prices</answer>

<question_number>3</question_number>
<answer>Lack of FDA oversight and quality control for compounded drugs</answer>

<question_number>4</question_number>
<answer>To recapture customers who are currently getting compounded versions, even if existing pen users switch to cheaper vials</answer>

<question_number>5</question_number>
<answer>When tirzepatide is removed from shortage list, compounding pharmacies will no longer be legally allowed to produce it</answer>

<question_number>6</question_number>
<answer>Lower prices achieved by removing third-party supply chain entities through direct sales</answer>

<question_number>7</question_number>
<answer>Older Medicare patients might seek the cheaper vials despite unique risks of muscle mass loss for their age group</answer>

<question_number>8</question_number>
<answer>Positions FDA-approved vials as a safer alternative to less regulated compounded versions</answer>

<question_number>9</question_number>
<answer>Being listed on FDA's shortage list</answer>

<question_number>10</question_number>
<answer>Lower pricing</answer>